文献速递类风湿关节炎脊柱关节炎

炎症性关节炎患者肺炎球菌疫苗接种率:单中心队列研究

Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该回顾性单中心队列研究纳入英国906例类风湿关节炎、银屑病关节炎和轴性脊柱关节炎患者,评估2023年10月至12月肺炎球菌、流感和新冠疫苗接种率及接种预测因素。结果显示35%接种肺炎球菌疫苗,低于流感(63%)和新冠(87%)疫苗;年龄≥65岁(OR 1.67;95%CI 1.21,2.29)、生物制剂治疗(OR 1.81;95%CI 1.33,2.47)及额外绿皮书指标(OR 1.67;95%CI 1.19,2.33)与接种率较高相关。作者认为炎症性风湿病患者肺炎球菌疫苗接种率低,尤其在年轻和未用生物制剂的患者中,需要针对性策略。

要点

  • 906例炎症性关节炎患者中仅35%接种肺炎球菌疫苗,低于流感疫苗63%和新冠疫苗87%的接种率。
  • 年龄≥65岁(OR 1.67;95%CI 1.21,2.29)和生物制剂治疗(OR 1.81;95%CI 1.33,2.47)与肺炎球菌疫苗接种率较高相关。
  • 额外绿皮书指标也正向影响接种率(OR 1.67;95%CI 1.19,2.33)。

核心结论

  • 炎症性风湿病患者的肺炎球菌疫苗接种率低,尤其在年轻和未使用生物制剂的患者中。
  • 该研究强调需要采取与其它疫苗策略不同的针对性方法来应对这一公共卫生挑战。

研究设计与样本

  • 回顾性单中心队列研究,于2023年10月至12月在英国纳入类风湿关节炎、银屑病关节炎和轴性脊柱关节炎患者。
  • 共纳入906例个体,收集年龄、性别、合并症、免疫抑制治疗和疫苗接种日期数据,采用logistic回归评估接种预测因素并校正人口学和临床因素。

主要发现

  • 906例中46%接受传统合成改善病情抗风湿药(csDMARD)治疗,26%接受生物制剂单药治疗,23%同时接受生物制剂和csDMARD治疗。
  • 316例(35%)接种肺炎球菌疫苗,低于流感疫苗(63%)和新冠疫苗(87%)的接种率。
  • 肺炎球菌疫苗接种的预测因素包括年龄,年龄≥65岁者接种可能性更高(OR 1.67;95%CI 1.21,2.29)。
  • 接受生物制剂治疗者接种可能性更高(OR 1.81;95%CI 1.33,2.47)。
  • 额外的疫苗接种和免疫联合委员会绿皮书指标也正向影响接种率(OR 1.67;95%CI 1.19,2.33)。

关键数值与推荐

  • 现行指南推荐年龄超过65岁或因病或治疗导致免疫抑制的个体接种肺炎球菌疫苗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Current guidelines recommend pneumococcal vaccination in individuals who are over the age of 65 or are immunosuppressed due to a disease or treatment. The objective of this study was to assess vaccine uptake rates in people with inflammatory arthritis for the pneumococcal, influenza and Covid-19 vaccines and factors determining uptake. METHODS: We conducted a retrospective single centre cohort study in the UK of individuals with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis between October and December 2023. Data were collected for age, gender, co-morbidities, immunosuppressive therapies and dates of vaccines. Logistic regression was used to evaluate predictors of vaccine uptake, with adjustments for demographic and clinical factors. RESULTS: Nine hundred and six individuals were identified; 46% were receiving treatment with conventional synthetic DMARD (csDMARD), 26% were on biologic monotherapy, and 23% were on both biologic and csDMARDs. Three hundred and sixteen individuals (35%) received a pneumococcal vaccine, lower than uptake for influenza (63%) and Covid-19 (87%) vaccines. Predictors of pneumococcal vaccine uptake included age, with older patients more likely to be vaccinated (odds ratio [OR] for age ≥ 65 years: 1.67; 95% CI: 1.21, 2.29). Those on biologic therapy demonstrated higher likelihood of vaccination (OR for biologic therapy: 1.81; 95% CI: 1.33, 2.47). Additional Joint Committee on Vaccination and Immunisation Green Book indicators also positively influenced vaccine uptake (OR: 1.67; 95% CI: 1.19, 2.33). CONCLUSION: Pneumococcal vaccine uptake in inflammatory rheumatic diseases is low, especially in younger patients and those not on biologic therapy. The study highlights the need for a focused approach, distinct from strategies for other vaccines, to address this public health challenge.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Nagra D, Bechman K, Russell MD, et al. Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort study. Rheumatology (Oxford). 2025. PMID: 38833673. doi:10.1093/rheumatology/keae305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。